Clinical and biological role of secretory phospholipase A2 in acute respiratory distress syndrome infants

Critical Care

Volumn 17, Issue 4, 2013, Pages

  De Luca, Daniele ^a   Lopez Rodriguez, Elena ^b   Minucci, Angelo ^a   Vendittelli, Francesca ^a   Gentile, Leonarda ^a   Stival, Eleonora ^a   Conti, Giorgio ^a   Piastra, Marco ^a   Antonelli, Massimo ^a   Echaide, Mercedes ^b   Perez Gil, Jesus ^b   Capoluongo, Ettore D ^a  

^a FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

FATTY ACID; SECRETORY PHOSPHOLIPASE A2; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; ARTIFICIAL VENTILATION; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HOSPITALIZATION; HUMAN; INFANT; INFANT DISEASE; INTENSIVE CARE; LUNG LAVAGE; LUNG MECHANICS; MALE; NEWBORN; OXYGEN THERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESPIRATORY DISTRESS SYNDROME; SURFACE TENSION; WESTERN BLOTTING; ENZYME ACTIVATION; ENZYMOLOGY; NEONATAL RESPIRATORY DISTRESS SYNDROME; PHYSIOLOGY; PROCEDURES;

BRONCHOALVEOLAR LAVAGE; ENZYME ACTIVATION; FEMALE; HUMANS; INFANT; MALE; PHOSPHOLIPASES A2, SECRETORY; RESPIRATION, ARTIFICIAL; RESPIRATORY DISTRESS SYNDROME, NEWBORN; SURFACE TENSION;

EID: 84880382167     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc12842     Document Type: Article

References (46)

1. Lambeau G, Gelb MH. Biochemistry and physiology of mammalian secreted phospholipases A2. Annu Rev Biochem 2008, 77:21.1-21.26.
2. Kitsiouli E, Nakos G, Lekka ME. Phospholipases A2 subclasses in acute respiratory distress syndrome. Biochim Biophys Acta 2009, 1792:1241-1248.
3. Furue S, Kuwabara K, Mikawa K, Nishina K, Shiga M, Maekawa N, Ueno M, Chikazawa Y, Ono T, Hori Y, Matsukawa A, Yoshinaga M, Obara H. Crucial role for group II-phospholipase A2 in oleic acid-induced acute lung injury in rabbits. Am J Resp Crit Care Med 1999, 160:1241-1248.
4. Furue S, Mikawa K, Nishina K, Shiga M, Ueno M, Tomita Y, Kuwabara K, Teshirogi I, Ono T, Hori Y, Matsukawa A, Yoshinaga M, Obara H. Therapeutic time-window of a group IIA phospholipase inhibitor in rabbit acute lung injury: correlation with lung surfactant protection. Crit Care Med 2001, 29:1241-1248.
5. Kim DK, Fukuda T, Thompson BT, Cockrill B, Hales C, Bonventre JV. Bronchoalveolar lavage fluid phospholipase A2 activities are increased in human adult respiratory distress syndrome. Am J Physiol 1995, 269:L109-118.
6. Nakos G, Kitsiouli E, Hatzidaki E, Koulouras V, Touqui L, Lekka ME. Phospholipases A2 and platelet activating-factor acetylhydrolase in patients with acute respiratory distress syndrome. Crit Care Med 2005, 33:1241-1248.
7. Randolph AG. Management of acute lung injury and acute respiratory distress syndrome i children. Crit Care Med 2009, 37:1241-1248.
8. Khemani RG, Newth CJL. The design of future pediatric mechanical ventilation trials for acute lung injury. Am J Resp Crit Care Med 2010, 182:1241-1248.
9. De Luca D, Cogo P, Zecca E, Piastra M, Pietrini D, Tridente A, Conti G, Carnielli VP. Intrapulmonary drug administration in neonatal/pediatric critical care: a comprehensive review. Eur Resp J 2011, 37:1241-1248.
10. Touqui L, Arbibe L. A role for phospholipase A2 in ARDS pathogenesis. Mol Med Tod 1999, 5:1241-1248.
11. Magrioti V, Kokotos G. Phospholipase A2 inhibitors as potential therapeutic agents for the treatment of inflammatory diseases. Expert Opin Ther Pat 2010, 20:1241-1248.
12. De Luca D, Minucci A, Cogo P, Capoluongo ED, Conti G, Pietrini D, Carnielli VP, Piastra M. Secretory phospholipase A2 pathway during pediatric ARDS: a preliminary study. Pediatr Crit Care Med 2011, 12:e20-e24. 10.1097/PCC.0b013e3181dbe95e, 20351613.
13. De Luca D, Capoluongo ED, Rigo V. for the Study group on Secretory Phospholipase in Paediatrics (SSPP) Secretory phospholipase A2 pathway in various types of lung injury in neonates and infants: a multicentre translational study. BMC Pediatrics 2011, 11:101. 10.1186/1471-2431-11-101, 3247178, 22067747, for the Study group on Secretory Phospholipase in Paediatrics (SSPP).
14. Bernard GR, Artigas A, Brigham KL, Carlet J, Falke K. and the Consensus Committee American-European Consensus Conference on ARDS Definition, mechanisms, relevant outcomes and clinical trial coordination. Am J Respir Crit Care Med 1994, 149:1241-1248. 10.1164/ajrccm.149.5.8173765, 8173765, and the Consensus Committee American-European Consensus Conference on ARDS.
15. Ventre KM, Arnold JH. High frequency oscillatory ventilation in acute respiratory failure. Pediatr Respir Rev 2004, 5:1241-1248.
16. Randolph AG, Wypij D, Venkataraman ST, Hanson JH, Gedeit RG, Meert KL, Luckett PM, Forbes P, Lilley M, Thompson J, Cheifetz IM, Hibberd P, Wetzel R, Cox PN, Arnold JH. Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network Effect of mechanical ventilator weaning protocols on respiratory outcomes in infants and children: A randomized controlled trial. JAMA 2002, 288:1241-1248. Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network.
17. European Respiratory Society Task Force on bronchoalveolar lavage in children Bronchoalveolar lavage in children. Eur Respir J 2000, 15:217-231. 10.1183/09031936.00.15121700, 10678650, European Respiratory Society Task Force on bronchoalveolar lavage in children.
18. De Luca D, Minucci A, Tripodi D, Piastra M, Pietrini D, Zuppi C, Conti G, Carnielli VP, Capoluongo E. Role of distinct phospholipases A2 and their modulators in meconium aspiration syndrome in human neonates. Intensive Care Med 2011, 37:1241-1248.
19. Reynolds LJ, Hughes LL, Dennis EA. Analysis of human synovial fluid phospholipase A2 on short chain phosphatidylcholine-mixed micelles: development of a spectrophotometric assay suitable for a microtiter plate reader. Anal Biochem 1992, 204:1241-1248.
20. Matsubara C, Nishikawa Y, Yoshida Y, Takamura K. A spectrophotometric method for the determination of free fatty acid in serum using acyl-coenzyme A synthetase and acyl-coenzyme A oxidase. Anal Biochem 1983, 130:1241-1248.
21. Greene KE, Wright JR, Steinberg KP, Ruzinski JT, Caldwell E, Wong WB, Hull W, Whitsett JA, Akino T, Kuroki Y, Nagae H, Hudson LD, Martin TR. Serial changes in surfactant-associated proteins in lung and serum before and after onset of ARDS. Am J Respir Crit Care Med 1999, 160:1241-1248.
22. Bradford M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976, 72:1241-1248.
23. Capoluongo E, Ameglio F, Lulli P, Minucci A, Santonocito C, Concolino P, Di Stasio E, Boccacci S, Vendettuoli V, Giuratrabocchetta G, De Cunto A, Tana M, Romagnoli C, Zuppi C, Vento G. Epithelial lining fluid free IGF-I-to-PAPP-A ratio is associated with bronchopulmonary dysplasia in preterm infants. Am J Physiol Endocrinol Metab 2007, 292:E308-E313.
24. Rouser G, Siakotos AN, Fleischer S. Quantitative analysis of phospholipids by thin-layer chromatography and phosphorus analysis of spots. Lipids 1966, 1:1241-1248.
25. Schuürch S, Bachofen H, Goerke J, Possmayer F. A captive bubble method reproduces the in situ behavior of lung surfactant monolayers. J Appl Physiol 1989, 67:1241-1248.
26. Goómez-Gil L, Schuürch D, Goormaghtigh E, Peórez-Gil J. Pulmonary surfactant protein SP-C counteracts the deleterious effects of cholesterol on the activity of surfactant films under physiologically relevant compression-expansion dynamics. Biophysical J 2009, 97:1241-1248.
27. López-Rodríguez E, Ospina OL, Echaide M, Taeusch TW, Pérez-Gil J. Exposure to polymers reverses inhibition of pulmonary surfactant by serum, meconium, or cholesterol in the captive bubble surfactometer. Biophysical J 2012, 103:1241-1248.
28. Schoel WM, Schuürch S, Goerke J. The captive bubble method for the evaluation of pulmonary surfactant: surface tension, area, and volume calculations. Biochim Biophys Acta 1994, 1200:1241-1248.
29. Pollack MM, Patel KM, Ruttimann UE. PRISM-III: an updated pediatric risk of mortality score. Crit Care Med 1996, 24:1241-1248.
30. Newth CJ, Stretton M, Deakers TW, Hammer J. Assessment of pulmonary function in the early phase of ARDS in pediatric patients. Ped Pulmonol 1997, 23:1241-1248.
31. Norusis M. SPSS 13.0 advanced statistical procedures companion 2004, Prentice Hall, NJ: Upper Saddle-River.
32. Arbibe L, Koumanov K, Vial D, Rougeot C, Faure G, Havet N, Longacre S, Vargaftig BB, Béréziat G, Voelker DR, Wolf C, Touqui L. Generation of lyso-phospholipids from surfactant in acute lung injury is mediated by type-II phospholipase A2 and inhibited by a direct surfactant protein A-phospholipase A2 protein interaction. J Clin Invest 1998, 102:1241-1248.
33. Chabot S, Koumanov K, Lambeau G, Gelb MH, Balloy V, Chignard M, Whitsett JA, Touqui L. Inhibitory effects of surfactant protein-A on surfactant phosoholipid hydrolysis by secreted phospholipases A2. J Immunol 2003, 171:1241-1248.
34. Seeds MC, Jones KA, Duncan Hite R, Willingham MC, Borgerink HM, Woodruff RD, Bowton DL, Bass DA. Cell-specific expression of group × and group V secretory phospholipase A2 in human lung airway epithelial cells. Am J Respir Cell Mol Biol 2000, 23:1241-1248.
35. Ohtsuki M, Taketomi Y, Arata S, Masuda S, Ishikawa Y, Ishii T, Takanezawa Y, Aoki J, Arai H, Yamamoto K, Kudo I, Murakami M. Transgenic expression of group V, but not group X, secreted phospholipase A2 in mice leads to neonatal lethality because of lung dysfunction. J Biol Chem 2006, 281:1241-1248.
36. Muñoz NM, Meliton AY, Meliton LN, Dudek SM, Leff AR. Secretory group V phospholipase A2 regulates acute lung injury and neutrophilic inflammation caused by LPS in mice. Am J Physiol Lung Cell Mol Physiol 2009, 296:L879-L887. 10.1152/ajplung.90580.2008, 2692807, 19286925.
37. Rae D, Porter J, Beechey-Newman N, Sumar N, Bennett D, Hermon-Taylor J. Type I phospholipase A2 propeptide in acute lung injury. Lancet 1994, 344:1241-1248. 10.1016/S0140-6736(94)90744-7, 7967981.
38. Kishino J, Ohara O, Nomura K, Kramer RM, Arita H. Pancreatic-type phospholipase A2 induces group II-phospholipase A2 expression and prostaglandin biosynthesis in rat mesangial cells. J Biol Chem 1994, 269:1241-1248.
39. Günther A, Ruppert C, Schmidt R, Markart P, Grimminger F, Walmrath D, Seeger W. Surfactant alteration and replacement in acute respiratory distress syndrome. Respir Res 2001, 2:1241-1248.
40. Casals C, Varela A, Ruano ML, Valiño F, Pérez-Gil J, Torre N, Jorge E, Tendillo F, Castillo-Olivares JL. Increase of C-reactive protein and decrease of surfactant protein A in surfactant after lung transplantation. Am J Respir Crit Care Med 1998, 157:1241-1248.
41. Markart P, Ruppert C, Wygrecka M, Colaris T, Dahal B, Walmrath D, Harbach H, Wilhelm J, Seeger W, Schmidt R, Guenther A. Patients with ARDS show improvement but not normalisation of alveolar surface activity with surfactant treatment: putative role of neutral lipids. Thorax 2007, 62:1241-1248.
42. Günther A, Siebert C, Schmidt R, Ziegler S, Grimminger F, Yabut M, Temmesfeld B, Walmrath D, Morr H, Seeger W. Surfactant alterations in severe pneumonia, acute respiratory distress syndrome and cardiogenic lung edema. Am J Respir Crit Care Med 1996, 153:1241-1248.
43. Hite RD, Seeds MC, Jacinto RB, Grier BL, Waite BM, Bass DA. Lysophospholipid and fatty acid inhibition of pulmonary surfactant: non-enzymatic models of phospholipase A2 surfactant hydrolysis. Biochim Biophys Acta 2005, 1720:1241-1248.
44. Hummer J. ARDS - Long term follow up. Paediatr Resp Rev 2006, 7S:S192-S193.
45. De Luca D, Minucci A, Gentile L, Piastra M, Antonelli M, Conti G, Capoluongo ED. Association between secretory phospholipase A2 subtype V (PLA2G5) genotype and acute respiratory distress in infants [abstract]. Arch Dis Child 2012, (Suppl 2):A16.
46. Hite RD, Grier BL, Waite BM, Veldhuizen RA, Possmayer F, Yao LJ, Seeds MC. Surfactant protein B inhibits secretory phospholipase A2 hydrolysis of surfactant phospholipids. Am J Physiol Lung Cell Mol Physiol 2012, 302:L257-265. 10.1152/ajplung.00054.2011, 3349360, 22037357.